

AI  
CONT. 49. A therapeutic composition useful in treating humans with *Moraxella catarrhalis* comprising at least one antibody directed against the polypeptide of claim 27 and a suitable pharmaceutical carrier.

---

**REMARKS**

**Claims**

Claims 1-26 have been canceled without prejudice or disclaimer of the subject matter therein. Applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims as originally filed, and any other claims supported by the specification.

New claims 27-49 have been introduced. No new matter is added.

**Support**

Support for the new claims is either apparent, or is as described in the text below. Support for the hybridization conditions may be found, for example, at page 14, fourth full paragraph. Support for the recitation of sequence relatedness such as in claim 40 may be found in the specification, for example, at pages 46-50.

**Closing Remarks**

Allowance of the pending claims is respectfully requested.

Respectfully submitted,



Teresa O. Bittenbender  
Registration No. 47,425  
Attorney for Applicant

DECHERT  
1717 Arch Street  
4000 Bell Atlantic Tower  
Philadelphia, PA 19103  
Fax: (215) 994-2222  
Attn: Teresa O. Bittenbender, Esq.  
(215) 994-2213